Case studies Welcome to the central library for all GS1 case studies. Use search or filters to discover case studies related to specific topics such as benefit, industry, service, standard or location. Search Industry Retail Marketplaces Healthcare Transport & Logistics Technical Industries Foodservice Public sector Region North America Latin America Country (-) Argentina Australia Austria Brazil Bulgaria Canada Chile China Chinese Taipei Colombia Denmark Ethiopia Germany Hong Kong India Ireland Italy Korea Malaysia Mexico Netherlands New Zealand Norway Pakistan Saudi Arabia Spain Switzerland Turkey United Kingdom (-) United States Zambia Benefits Data quality Regulatory compliance Safety Traceability Standards GTIN GLN 1D barcodes 2D barcodes GPC GS1 DataMatrix RFID Services Verified by GS1 GDSN Type of organisation Retailer Manufacturer (-) Government Healthcare provider (-) Solution provider Logistics provider Distributor Small & Medium Enterprises (-) Argentina (-) United States (-) Government (-) Solution provider Clear all filters Showing 8 results Healthcare Barcode readability for DSCSA 2023 interoperability AmerisourceBergen and McKesson conducted barcode assessments to gain an up-to-date view of industry’... Healthcare 1WorldSync: Leveraging the GDSN to improve the healthcare supply chain Complete and accurate master product data are essential for healthcare providers to deliver the best... Healthcare, Public sector Collaborating with the USA FDA on Unique Device Identification The Unique Device Identification (UDI) is a system used to mark and identify medical devices within ... Healthcare, Public sector ANMAT leading the way: A new contribution to the safety of drugs in Argentina Traceability of medicines has been the object of a broad and fruitful evolution, resulting in Argent... GS1 Standards Help Government and Industry Work Smarter Better Immunisation Management for Patient Safety Change has finally come: U.S. Healthcare industry to implement common data standards to im... Experience in traceability of essential drugs in the public sector
